Feely J, Stevenson I H, Crooks J
Clin Pharmacol Ther. 1980 Jul;28(1):40-4. doi: 10.1038/clpt.1980.128.
Twenty-five thyrotoxic patients were treated with propranolol (160 mg/day) for 1 to 2 wk. Although the response to therapy varied there was a reduction (p less than 0.001) in supine and exercise heart rates and in sitting pulse rate. Serum triiodothyronine (T3) fell (p less than 0.001) and serum thyroxine did not change during propranolol therapy. Plasma propranolol levels before assessment varied from 5 to 121 ng/ml, and there were positive correlations between them and percentage reduction in exercise (r = 0.78, p less than 0.001) and resting (r = 0.61, n = 14, p less than 0.05) heart rates, percentage reduction in sitting pulse rate (r = 0.73, p less than 0.001), and the percentage reduction in serum T3 (r = 0.59, n = 23, p less than 0.01). Although weight loss ceased in the group as a whole the degree of continued weight loss or weight gain in individual patients was also related to plasma propranolol concentration (r = 0.61, p less than 0.01). The plasma propranolol level correlated (r = 0.62, p less than 0.01) with thyrotoxicosis therapeutic index. There was no correlation between degress of subjective improvement and plasma propranolol level.
25例甲状腺毒症患者接受普萘洛尔（160毫克/天）治疗1至2周。尽管治疗反应各不相同，但仰卧和运动时的心率以及坐位脉搏率均有所降低（p<0.001）。在普萘洛尔治疗期间，血清三碘甲状腺原氨酸（T3）下降（p<0.001），而血清甲状腺素未发生变化。评估前血浆普萘洛尔水平在5至121纳克/毫升之间，它们与运动时心率降低百分比（r=0.78，p<0.001）、静息时心率降低百分比（r=0.61，n=14，p<0.05）、坐位脉搏率降低百分比（r=0.73，p<0.001）以及血清T3降低百分比（r=0.59，n=23，p<0.01）之间存在正相关。尽管总体上该组患者体重停止减轻，但个别患者持续体重减轻或体重增加的程度也与血浆普萘洛尔浓度有关（r=0.61，p<0.01）。血浆普萘洛尔水平与甲状腺毒症治疗指数相关（r=0.62，p<0.01）。主观改善程度与血浆普萘洛尔水平之间无相关性。
